Business context and reporting period
The supplied filing is Obalon Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019—not a filing for Vyome Holdings, Inc. Obalon develops and sells the FDA-approved Obalon Balloon System for weight loss. It began commercial shipments of its Navigation System and Touch Inflation Dispenser in Q1 2019 and completed final shipments to its Middle East distributor.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / comparator |
|---|---|---|
| Revenue | $1.775 million | $1.346 million |
| Gross profit / margin | $0.543 million / 31% | $0.577 million / 43% |
| Operating expenses | $8.643 million | $12.645 million |
| Net loss | $8.290 million; $0.36 per share | $12.126 million; $0.71 per share |
| Cash used in operations | $9.642 million | $10.602 million |
| Cash and cash equivalents at quarter-end | $24.684 million | $21.187 million at Dec. 31, 2018 |
| Debt outstanding | $20.0 million | $10.0 million at Dec. 31, 2018 |
Revenue rose about 32% year over year, but gross profit fell and gross margin contracted, primarily due to lower margins on the new Navigation System products. SG&A declined to $6.204 million from $10.006 million, chiefly reflecting lower personnel, investigation-related, marketing and commission costs; R&D was $2.439 million versus $2.639 million. Net loss narrowed, while interest expense increased following the additional loan draw.
Cash increased by $3.497 million during the quarter, supported by $10.0 million of new borrowing, $0.6 million of net stock proceeds and $2.5 million of investment maturities. Current assets were $29.912 million and current liabilities $25.031 million; the latter includes the entire $19.952 million net loan balance, reclassified as current amid liquidity and going-concern concerns. The lender requires cash balances at least equal to debt outstanding, leaving only about $4.7 million of reported cash effectively available at March 31. Accumulated deficit was $157.0 million.
Material changes, outlook and risks
- Management stated there was substantial doubt about the company’s ability to continue as a going concern. It warned that without additional capital in Q2 2019, it could not support ongoing operations. Options included raising capital, renegotiating the bank’s cash-collateral covenant or pursuing a strategic alternative; bankruptcy was identified as a possible outcome if alternatives failed.
- After quarter-end, on April 2, the company announced the planned termination of about 49 employees, roughly half its workforce, including elimination of its field sales organization and a move to centralized customer support. It recorded a $0.5 million restructuring charge in April and expected $0.7–$0.9 million of stock-compensation reversals. Management said it could not predict whether the new sales model would work.
- On April 11, the company engaged Cowen to explore financial and strategic opportunities. No specific transaction or financial guidance was provided. The company said it did not expect further international revenue in 2019 after final Middle East shipments.
- The Lincoln Park agreement permits up to $20 million of stock sales, but proceeds depend on market price and other limits; $1.3 million had been raised by March 31. The ATM agreement permits up to $10 million, but only an immaterial amount had been sold by quarter-end. Both involve potential dilution, and the filing notes limits on access to these funds.
- Other important risks include the immature market and uncertain physician adoption; transition to the Navigation System and centralized support; manufacturing and single-source supplier constraints; product safety and regulatory requirements; and a shareholder class action. The company had paused new enrollment in its post-approval study to conserve cash, subject to FDA review. It reported compliance with loan covenants at March 31.
Important facts for investors to verify
- Confirm the issuer: the source is Obalon Therapeutics, Inc., not Vyome Holdings, Inc.
- Check whether Obalon obtained financing, renegotiated its cash-collateral covenant or completed a strategic transaction after May 10, 2019, and whether it maintained the lender-required balance.
- Review the actual cash available for operations, near-term cash burn, and the status and terms of any ATM or Lincoln Park stock sales.
- Assess the impact of the workforce reduction on sales, customer support, product returns, collections and operating costs.
- Track gross margins and adoption of the Navigation System, the FDA’s response to the paused study, the shareholder litigation and Nasdaq listing compliance.